6.
Keech C, Miller V, Rizzardi B, Hoyle C, Pryor M, Ferrand J
. Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus-diphtheria-acellular pertussis vaccine: a randomised, double-blind, phase 2b trial. Lancet. 2023; 401(10379):843-855.
DOI: 10.1016/S0140-6736(22)02644-7.
View
7.
De Serres G, Shadmani R, Duval B, Boulianne N, Dery P, Fradet M
. Morbidity of pertussis in adolescents and adults. J Infect Dis. 2000; 182(1):174-9.
DOI: 10.1086/315648.
View
8.
Middleton D, Clark L, Mosnier A, Heininger U
. Pertussis vaccination in adults: a behavioral study of physicians from the US, France, and Germany. BMC Prim Care. 2024; 25(1):402.
PMC: 11590461.
DOI: 10.1186/s12875-024-02647-3.
View
9.
Rodrigues C, Bouchez V, Soares A, Trombert-Paolantoni S, Ait El Belghiti F, Cohen J
. Resurgence of , including one macrolide-resistant isolate, France, 2024. Euro Surveill. 2024; 29(31).
PMC: 11295439.
DOI: 10.2807/1560-7917.ES.2024.29.31.2400459.
View
10.
See K
. Enhancing COVID-19 Vaccination Awareness and Uptake in the Post-PHEIC Era: A Narrative Review of Physician-Level and System-Level Strategies. Vaccines (Basel). 2024; 12(9).
PMC: 11435511.
DOI: 10.3390/vaccines12091038.
View
11.
Guzman-Holst A, Gomez J, Cintra O, Van Oorschot D, Jamet N, Nieto-Guevara J
. Assessing the Underestimation of Adult Pertussis Disease in Five Latin American Countries. Infect Dis Ther. 2023; 12(12):2791-2806.
PMC: 10746655.
DOI: 10.1007/s40121-023-00895-x.
View
12.
Altunaiji S, Kukuruzovic R, Curtis N, Massie J
. Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev. 2007; (3):CD004404.
PMC: 11322855.
DOI: 10.1002/14651858.CD004404.pub3.
View
13.
Zhu Y, Sun L, Wang Y, Wang J, Wang Y, Li J
. Adverse events following immunization of co- and separate administration of DTaP-IPV/Hib vaccines: A real-world comparative study. Hum Vaccin Immunother. 2024; 20(1):2372884.
PMC: 11225913.
DOI: 10.1080/21645515.2024.2372884.
View
14.
Kovac M, Kostanyan L, Mesaros N, Kuriyakose S, Varman M
. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center.... Hum Vaccin Immunother. 2018; 14(8):1977-1986.
PMC: 6149833.
DOI: 10.1080/21645515.2018.1460292.
View
15.
Macina D, Mathur S, Dvaretskaya M, Ekhtiari S, Hayat P, Montmerle M
. Estimating the pertussis burden in adolescents and adults in the United States between 2007 and 2019. Hum Vaccin Immunother. 2023; 19(1):2208514.
PMC: 10184607.
DOI: 10.1080/21645515.2023.2208514.
View
16.
Plans-Rubio P
. Vaccination Coverage for Routine Vaccines and Herd Immunity Levels against Measles and Pertussis in the World in 2019. Vaccines (Basel). 2021; 9(3).
PMC: 7999208.
DOI: 10.3390/vaccines9030256.
View
17.
Zimmerman R, Barker W, Strikas R, Ahwesh E, Mieczkowski T, Janosky J
. Developing curricula to promote preventive medicine skills. The Teaching Immunization for Medical Education (TIME) Project. TIME Development Committee. JAMA. 1997; 278(9):705-11.
View
18.
. Pertussis vaccine injury. AMA Ad Hoc Panel on Pertussis Vaccine Injury. JAMA. 1985; 254(21):3083-4.
View
19.
. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months --- Advisory Committee on.... MMWR Morb Mortal Wkly Rep. 2011; 60(41):1424-6.
View
20.
Eiden A, Hartley L, Garbinsky D, Saande C, Russo J, Gabriel M
. Adult vaccination coverage in the United States: A database analysis and literature review of improvement strategies. Hum Vaccin Immunother. 2024; 20(1):2381283.
PMC: 11290753.
DOI: 10.1080/21645515.2024.2381283.
View